США - англійська - NLM (National Library of Medicine)

fresenius kabi usa, llc - vasopressin (unii: y87y826h08) (vasopressin - unii:y87y826h08) - vasopressin 20 [usp'u] in 1 ml - vasopressin injection, usp is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus. anaphylaxis or hypersensitivity to the drug or its components.

США - англійська - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 4 ug in 1 ml - hemophilia a: desmopressin acetate injection 4 mcg/ml is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5%. desmopressin acetate injection will often maintain hemostasis in patients with hemophilia a during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. desmopressin acetate injection will also stop bleeding in hemophilia a patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. in certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor viii levels between 2% to 5%; however, these patients should be carefully monitored. von willebrand’s disease (type i): desmopressin acetate injection 4 mcg/ml is indicated for patients with mild to moderate classic von willebrand’s disease (type i) with factor viii levels greater than 5%. desmopressin acetate injection will often ma

США - англійська - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 0.1 mg in 1 ml - central cranial diabetes insipidus: desmopressin nasal spray solution, usp 0.01% is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. it is ineffective for the treatment of nephrogenic diabetes insipidus.   the use of desmopressin nasal spray solution, usp 0.01% in patients with an established diagnosis will result in a reduction in urinary output with increase in urine osmolality and a decrease in plasma osmolality. this will allow the resumption of a more normal life-style with a decrease in urinary frequency and nocturia.   there are reports of an occasional change in response with time, usually greater than 6 months. some patients may show a decreased responsiveness, others a shortened duration of effect. there is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the p

Канада - англійська - Health Canada

pharmascience inc - desmopressin acetate (desmopressin acetate trihydrate) - tablet - 0.1mg - desmopressin acetate (desmopressin acetate trihydrate) 0.1mg - pituitary

Канада - англійська - Health Canada

pharmascience inc - desmopressin acetate (desmopressin acetate trihydrate) - tablet - 0.2mg - desmopressin acetate (desmopressin acetate trihydrate) 0.2mg - pituitary

Канада - англійська - Health Canada

ferring inc - desmopressin acetate - tablet - 0.1mg - desmopressin acetate 0.1mg - pituitary

Канада - англійська - Health Canada

ferring inc - desmopressin acetate - tablet - 0.2mg - desmopressin acetate 0.2mg - pituitary

Канада - англійська - Health Canada

apotex inc - desmopressin acetate - tablet - 0.1mg - desmopressin acetate 0.1mg - pituitary

Канада - англійська - Health Canada

apotex inc - desmopressin acetate - tablet - 0.2mg - desmopressin acetate 0.2mg - pituitary

Канада - англійська - Health Canada

teva canada limited - desmopressin acetate - tablet - 0.1mg - desmopressin acetate 0.1mg - pituitary